Application of isobavachalcone and amphotericin B in preparation of antifungal drugs

By combining isopsoralen chalcone and amphotericin B, the problems of high concentration and drug resistance of isopsoralen chalcone were solved, achieving the effect of inhibiting Cryptococcus neoformans with low dose, reducing toxicity and improving the efficacy of treating Cryptococcus neoformans.

CN118976036APending Publication Date: 2024-11-19SHAANXI UNIV OF SCI & TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410839477.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing drugs for inhibiting Cryptococcus neoformans prepared from isopsoralen chalcone have high concentrations, significant side effects, and are prone to producing drug-resistant strains when used in combination with chemical drugs. Furthermore, isopsoralen chalcone has not been used as an adjuvant for amphotericin B in inhibiting or killing Cryptococcus neoformans.

Method used

A combination of isopsoralen chalcone and amphotericin B in a mass ratio of 0.0625–8:0.0625–8 is provided for the preparation of antifungal drugs. The minimum inhibitory concentration is determined by the twofold dilution method and the agar diffusion method. The combined use significantly reduces the drug dosage and improves the antifungal effect.

Benefits of technology

It significantly reduces drug dosage, improves antifungal efficacy, reduces toxicity, decreases drug-resistant strains, provides a new method for treating Cryptococcus neoformans, and reduces treatment costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976036A_ABST
    Figure CN118976036A_ABST
Patent Text Reader

Abstract

The invention discloses an application of an isobavachalcone and amphotericin B combined drug in preparation of an antifungal drug, a natural antifungal substance is searched from a natural medicinal plant resource library, the MIC of isobavachalcone is determined to be 8 mu g / mL through a double dilution method and an agar diffusion method, the MIC of amphotericin B is determined to be 1 mu g / mL, and the MIC of isobavachalcone and amphotericin B is determined to be 8 mu g / mL through a double dilution method and an agar diffusion method. When the isobavachalcone and the amphotericin B are used in a combined manner, the use dosages of the isobavachalcone and the amphotericin B are remarkably reduced, the MIC of the isobavachalcone is reduced to 4 mu g / mL, the MIC of the amphotericin B is reduced to 0.125 mu g / mL, and the composition has a remarkable bactericidal effect on cryptococcus neoformans H99, so that the use dosage of the composition can be remarkably reduced, the bactericidal effect can be improved, and the composition is suitable for clinical application. Epsilon-is 0 according to an epsilon-value calculation formula, and the effect of drug combination of the two on cryptococcus neoformans is further confirmed to be a synergistic effect. The invention provides a new material and a new idea for solving deep fungal infection, and has important clinical application values for improving the curative effect of the antifungal drug, reducing the side effect of the drug, reducing the treatment cost and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to application of isopsoralea corylifolia chalcone and amphotericin B in the preparation of antifungal drugs. Background Art

[0002] Fungal pathogens infect more than 1 billion people worldwide, and invasive fungal infections have a higher mortality rate, causing more deaths each year than tuberculosis or malaria. An estimated 223,100 cases of cryptococcal meningitis occur worldwide each year, resulting in 181,100 deaths. Most deaths occur in resource-limited countries due to the lack of drugs and the high cost of effective treatment, so there is an urgent need to develop highly effective, less toxic, and less expensive treatments for C. neoformans that can replace antibiotics. Treatment options for invasive cryptococcal infections are limited because cryptococci are intrinsically resistant to echinocandins and are highly susceptible to developing resistance to azoles. Therefore, amphotericin B has been the mainstay of treatment for cryptococcal infections for more than half a century, despite the fact that it causes tremendous toxicity, long-term administration of AMB can lead to renal failure, hypokalemia, hypomagnesemia, and anemia, and its availability is limited by economic development and geographical restrictions.

[0003] Amphotericin B is a polyene antifungal antibiotic, currently suitable for systemic infections caused by Cryptococcus, Coccidioides, Candida, Mucor, Aspergillus, etc. Among them, injectable amphotericin B liposomes have been widely used worldwide for 30 years and are known as the "gold standard" for the treatment of invasive fungal diseases. Although amphotericin B is effective against fungi, it has serious side effects, such as nephrotoxicity. In order to reduce the side effects of amphotericin B, scientists have modified amphotericin B to reduce its toxicity. Currently, there are amphotericin B liposomes, amphotericin B cholesterol complexes, amphotericin B deoxycholate and other dosage forms, but the availability of its liposome form is limited due to high costs and lack of safe intravenous administration. In addition, adverse drug reactions can also be minimized by reducing the drug dose, but the current methods of modifying benign amphotericin B to reduce its toxicity are still not effective, and it is impossible to achieve low-dose fungal inhibition with few side effects. Therefore, a new method of improving amphotericin B to reduce toxicity is urgently needed. Another way to reduce toxicity and improve efficacy is combination therapy, which improves bioavailability and minimizes toxic effects compared to amphotericin B alone. Many active compounds isolated from plants have been shown to have antibacterial activity against Cryptococcus neoformans. Combination therapy can reduce effective drug concentrations, reduce resistant strains, thereby improving therapeutic efficacy, and reduce toxicity by neutralizing or eliminating adverse reactions.

[0004] Isobavachalcone (IBC) is a natural flavonoid substance, belonging to the chalcone component of the traditional Chinese medicine psoralea corylifolia, also known as psoralen. The molecular formula is C 20 H 20 O4, molecular weight is 324.37, CAS number is 20784-50-3, the applicant's previous patent (CN 116421588 A) reported that isopsoralea chalcone can be used for the preparation of drugs to inhibit Cryptococcus neoformans, but the drug concentration is high and there are side effects in practical applications. The Chinese patent (CN 117679412 A) discloses the use of isopsoralea chalcone and fluconazole in the preparation of antifungal drugs, but the combination of chemical drugs and isopsoralea chalcone is used, which is easy to produce drug-resistant strains in clinical applications and has high cost. At present, there is no relevant report on the use of isopsoralea chalcone as an adjuvant for amphotericin B antifungal in inhibiting or killing Cryptococcus neoformans. Summary of the invention

[0005] The invention aims to provide an application of isopsoralea chalcone and amphotericin B in the preparation of an antifungal drug for inhibiting Cryptococcus neoformans, wherein the drug concentration is high and the side effects are large, and the drug-resistant strains are easily generated when used in combination with chemical drugs in clinical practice, and there is no literature or patent reporting on the technical status of the application of isopsoralea chalcone as an antifungal adjuvant of amphotericin B in inhibiting or killing Cryptococcus neoformans.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The invention provides an antifungal compound pharmaceutical composition, which comprises isopsoralea corylifolia chalcone and amphotericin B.

[0008] The fungus is Cryptococcus neoformans.

[0009] The mass ratio of the isopsoralea corylifolia chalcone to amphotericin B is 0.0625-8:0.0625-8.

[0010] The minimum inhibitory concentrations of the combined use of isopsoralea chalcone and amphotericin B on Cryptococcus neoformans are 4-8 μg / mL of isopsoralea chalcone and 0.125-1 μg / mL of amphotericin B, respectively.

[0011] Furthermore, the minimum inhibitory concentrations of the combination of isopsoralea chalcone and amphotericin B against Cryptococcus neoformans are 4 μg / mL of isopsoralea chalcone and 0.125 μg / mL of amphotericin B, respectively.

[0012] The antifungal compound pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0013] The pharmaceutically acceptable excipients are selected from at least one of pharmaceutically acceptable solvents, solubilizers, cosolvents, adhesives, emulsifiers, colorants, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, preservatives, flavoring agents, suspending agents, coating materials, fragrances, anti-adhesives, pH regulators, integrators, penetration enhancers, buffers, plasticizers, surfactants, humectants, thickeners, inclusion agents, absorbents, release retardants, diluents, flocculants and deflocculating agents, filter aids, polymer skeleton materials and film-forming materials.

[0014] The antifungal compound pharmaceutical composition is in the form of capsules, gels, creams, mixtures, tablets, powders, pills, granules, wet compresses, solutions, syrups, suppositories, decoctions, aerosols, ointments, plasters, injections, sprays, tinctures, liniments, pastes or lotions.

[0015] The present invention provides an application of the antifungal compound medicine composition in the preparation of an anti-cryptococcus neoformans medicine.

[0016] The anti-Cryptococcus neoformans includes inhibiting the growth of Cryptococcus neoformans, killing Cryptococcus neoformans and / or treating diseases caused by Cryptococcus neoformans infection; and / or, the isopsoralea chalcone can reduce the dosage of amphotericin B used on Cryptococcus neoformans and the anti-Cryptococcus neoformans effect.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The invention provides an application of the combined use of isopsoralea chalcone and amphotericin B in the preparation of an antifungal drug, and seeks natural antibacterial substances from a natural medicinal plant resource library. The invention determines that the MIC of isopsoralea chalcone is 8 μg / mL and the MIC of amphotericin B is 1 μg / mL by a two-fold dilution method and an agar diffusion method. When isopsoralea chalcone and amphotericin B are used in combination, the dosage of the drug is significantly reduced, and the MIC of isopsoralea chalcone is reduced to 4 μg / mL, and the MIC of amphotericin B is reduced to 0.125 μg / mL. This indicates that the combined use of the two can significantly reduce the dosage of the drug and improve the antifungal effect. Through the determination of growth curves and drug sensitivity experiments, the combined medication group had a significant bactericidal effect on Cryptococcus neoformans H99 at a concentration of 4 μg / mL isopsoralea chalcone and 0.125 μg / mL amphotericin B. Combined with the ε~ value calculation formula, ε~ was obtained to be 0, further confirming that the combined administration of the two had a synergistic effect on Cryptococcus neoformans; the use of the combined medication of isopsoralea chalcone and amphotericin B provided by the present invention in the preparation of antifungal drugs not only significantly reduced the dosage of the drug, improved the antifungal effect, but also provided a new idea for solving deep fungal infections. This achievement is of great significance in improving the efficacy of antifungal drugs, reducing drug side effects, and reducing treatment costs, and has important clinical application value.

[0019] The invention discloses an application of a combined use of isopsoralea chalcone and amphotericin B in preparing an antifungal drug, wherein natural antibacterial substances are sought from a natural medicinal plant resource library, based on the fact that isopsoralea chalcone inhibits the synthesis of ergosterol and destroys the stability of fungal cell membranes, thereby exerting an antibacterial effect; meanwhile, amphotericin B (AMB), as a polyene antifungal drug, combines with ergosterol in the fungal cell membrane to form holes, thereby causing a change in the permeability of the cell membrane, thereby achieving an antifungal effect, and solving the problems that the drug preparation for inhibiting Cryptococcus neoformans using isopsoralea chalcone has a high drug concentration, a large side effect, and is easily resistant to drug strains when used in combination with chemical drugs in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a graph showing the MIC test results of the isopsoralea corylifolia chalcone against Cryptococcus neoformans H99 of the present invention;

[0021] Figure 2 This is a graph showing the MIC test results of amphotericin B against Cryptococcus neoformans H99 of the present invention;

[0022] Figure 3 This is the time-killing curve result of the combination of isopsoralea corylifolia chalcone and amphotericin B against Cryptococcus neoformans H99;

[0023] Figure 4This is the drug sensitivity result of the combination of Psoralea corylifolia chalcone and amphotericin B against Cryptococcus neoformans H99. DETAILED DESCRIPTION

[0024] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0025] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0026] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0027] The invention provides an antifungal compound pharmaceutical composition, which comprises isopsoralea corylifolia chalcone and amphotericin B.

[0028] The fungus is Cryptococcus neoformans.

[0029] The mass ratio of the isopsoralea corylifolia chalcone to amphotericin B is 0.0625-8:0.0625-8.

[0030] The minimum inhibitory concentrations of the combined use of isopsoralea chalcone and amphotericin B on Cryptococcus neoformans are 4-8 μg / mL of isopsoralea chalcone and 0.125-1 μg / mL of amphotericin B, respectively.

[0031] Furthermore, the minimum inhibitory concentrations of the combination of isopsoralea chalcone and amphotericin B against Cryptococcus neoformans are 4 μg / mL of isopsoralea chalcone and 0.125 μg / mL of amphotericin B, respectively.

[0032] The antifungal compound pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0033] The pharmaceutically acceptable excipients are selected from at least one of pharmaceutically acceptable solvents, solubilizers, cosolvents, adhesives, emulsifiers, colorants, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, preservatives, flavoring agents, suspending agents, coating materials, fragrances, anti-adhesives, pH regulators, integrators, penetration enhancers, buffers, plasticizers, surfactants, humectants, thickeners, inclusion agents, absorbents, release retardants, diluents, flocculants and deflocculating agents, filter aids, polymer skeleton materials and film-forming materials.

[0034] The antifungal compound pharmaceutical composition is in the form of capsules, gels, creams, mixtures, tablets, powders, pills, granules, wet compresses, solutions, syrups, suppositories, decoctions, aerosols, ointments, plasters, injections, sprays, tinctures, liniments, pastes or lotions.

[0035] The present invention provides an application of the antifungal compound medicine composition in the preparation of an anti-cryptococcus neoformans medicine.

[0036] The anti-Cryptococcus neoformans includes inhibiting the growth of Cryptococcus neoformans, killing Cryptococcus neoformans and / or treating diseases caused by Cryptococcus neoformans infection; and / or, the isopsoralea chalcone can reduce the dosage of amphotericin B used on Cryptococcus neoformans and the anti-Cryptococcus neoformans effect.

[0037] The experimental strain of the present invention: Cryptococcus neoformans H99 (C. neoformans H99) was stored in the Microbiology Laboratory of the School of Food Science and Engineering of Shaanxi University of Science and Technology.

[0038] The dimethyl sulfoxide (DMSO), physiological saline, methanol, yeast extract, glucose, peptone, and RPMI-1640 used in the present invention were all purchased from Shanghai Sigma-Aldrich Trading Co., Ltd.; the pure isopsoralea corylifolia chalcone (HPLC≥98%; CAS: 20784-50-3) was purchased from Chengdu Lemeitian Pharmaceutical Technology Co., Ltd.; and the pure amphotericin B (HPLC≥98%; CAS: 1397-89-3) was purchased from Santa Cruz Biotechnology.

[0039] The YPD liquid culture medium used in the present invention is prepared by weighing 5 g of yeast extract powder, 10 g of glucose and 10 g of peptone, adding 500 mL of distilled water, and sterilizing with high pressure steam at 121° C. for 30 min.

[0040] 1% DMSO solution: Measure 99 mL of water, add 1 mL of 100% DMSO and mix well.

[0041] The test instruments used in the present invention include: high pressure sterilizer (Tianjin Test Instrument Co., Ltd.); DH6000A electric constant temperature incubator (Tianjin Test Instrument Co., Ltd.); clean bench (Suzhou Su Clean Equipment Co., Ltd.); 96-well plate (Denmark Thermo Fisher Scientific Co., Ltd.); electronic balance (Shanghai Jinke Tianmei Co., Ltd.); and microplate reader (Shenzhen Mindray Bio-Medical Co., Ltd.).

[0042] Example 1: Application of Isopsoralea corylifolia Chalcone and Amphotericin B in Combination Therapy

[0043] This example provides an application of the combined use of isopsoralea corylifolia chalcone and amphotericin B, and the specific experimental process is as follows:

[0044] (1) Preparation of drugs

[0045] 0.01 g of Psoralea corylifolia chalcone was accurately weighed and dissolved in 1 mL of DMSO to obtain a Chinese medicine component solution; the Chinese medicine component solution was then prepared into a drug stock solution with a concentration of 10 mg / mL using RPMI-1640 liquid culture medium; and the solution was diluted in multiples using RPMI-1640 culture medium to obtain drugs of different concentrations for measuring MIC; 0.01 g of amphotericin B was weighed and dissolved in 1 mL of DMSO to obtain a 10 mg / mL drug stock solution, and the solution was diluted in multiples using RPMI-1640 culture medium to obtain drugs of different concentrations for measuring MIC.

[0046] (2) Preparation of bacterial solution

[0047] Cryptococcus neoformans H99 stored at -20°C was inoculated into different glass test tubes containing 5 mL of RPMI-1640 liquid medium using an inoculation loop under sterile operation conditions, and then placed in a 30°C constant temperature incubator for 24 h until the logarithmic growth phase, and the OD was measured using a full-wavelength scanning multifunctional microplate reader. 600 , Cryptococcus neoformans H99 was subcultured and purified using the same inoculation method (subculture purification ensures the uniformity of the strain, generally one generation is sufficient) and then diluted to 1.0×10 6 CFU / mL, for future use.

[0048] (3) Determination of the minimum inhibitory concentration (MIC) of isopsoralea corylifolia chalcone against Cryptococcus neoformans H99

[0049] The doubling dilution method determines the antibacterial efficacy of a drug by measuring the growth of an equal amount of bacterial solution in a liquid culture medium containing different concentrations of the drug, as well as the turbidity of the culture medium after growth. The lowest concentration of the drug that inhibits the growth of the test bacteria measured by the dilution method is called the "minimum inhibitory concentration". The antibacterial activity was determined by the two-fold dilution method of a 96-well plate. Each well was added with 100 μL of isopsoralea corylifolia chalcone diluted to different concentrations, and then 100 μL of the diluted bacterial solution was added to make the final system 200 μL. A negative control group containing only bacterial solution and a positive control group of amphotericin B (100 μL of amphotericin B solution and 100 μL of bacterial solution) were set up. Each group repeated 5 parallel experiments to ensure the credibility of the experimental data. The concentration settings of the experimental groups are shown in Table 1.

[0050] Table 1: Final concentration of IBC in experimental group

[0051] Group Final concentration (μg / mL) Liquid 1 256 Liquid 2 128 Liquid 3 64 Liquid 4 32 Liquid 5 16 Liquid 6 8 Liquid 7 4 Liquid 8 2 Liquid 9 1 Liquid 10 0.5 Negative control (RPMI-1640) 0 Positive control (amphotericin B) 2

[0052] Each group of experiments was cultured in a 30°C constant temperature incubator for 24 h and then the OD was measured. 600 The lowest concentration of the drug in the wells with no bacterial growth was taken as the minimum inhibitory concentration (MIC) of the drug against Cryptococcus neoformans H99. For specific results, see Table 2 and Appendix Figure 1 shown.

[0053] Table 2: Inhibition results of Psoralea corylifolia chalcone on Cryptococcus neoformans H99

[0054]

[0055] From the data in Table 2 and the attached Figure 1 It can be seen that the minimum inhibitory concentration of Psoralea corylifolia chalcone against Cryptococcus neoformans H99 is 8 μg / mL.

[0056] (4) Determination of the minimum inhibitory concentration (MIC) of amphotericin B against Cryptococcus neoformans H99

[0057] Add 100 μL of amphotericin B diluted to different concentrations to each well, and then add 100 μL of bacterial solution to the 96-well plate. Make the final system 200 μL. Set up a negative control group containing only bacterial solution and a positive control group of amphotericin B (100 μL of amphotericin B solution and 100 μL of bacterial solution). Repeat 5 parallel experiments in each group to ensure the credibility of the experimental data. See Table 3 for the concentration settings of the experimental groups.

[0058] Table 3: Final concentration of amphotericin B in experimental groups

[0059] Group Final concentration (μg / mL) Liquid 2 16 Liquid 3 8 Liquid 4 4 Liquid 5 2 Liquid 6 1 Liquid 7 0.5 Liquid 8 0.25 Liquid 9 0.125 Liquid 10 0.0625 Negative control (RPMI-1640) 0 Positive control (amphotericin B) 2

[0060] Each group of experiments was cultured in a 30°C constant temperature incubator for 24 h and the results were observed and the OD 600The lowest concentration of the drug in the wells with no bacterial growth was taken as the minimum inhibitory concentration (MIC) of the drug against Cryptococcus neoformans H99. For specific results, see Table 4 and Appendix Figure 2 shown.

[0061] Table 4: Inhibition results of amphotericin B against Cryptococcus neoformans H99

[0062]

[0063] From Table 4 and the attached Figure 2 The data show that amphotericin B has a good inhibitory effect on Cryptococcus neoformans H99, and the minimum inhibitory concentration of amphotericin B against Cryptococcus neoformans H99 is 1 μg / mL.

[0064] Example 2: Determination of the interaction between isopsoralea corylifolia chalcone and amphotericin B by chessboard microdilution method

[0065] According to the checkerboard microdilution assay of the CLSIM27-A3 scheme, the minimum inhibitory concentration of each drug was determined. The drug concentration range used in this experiment was determined based on its minimum inhibitory concentration, and the above drug stock solution was diluted with RPMI-1640 liquid culture medium to obtain amphotericin B solutions with final concentrations of 8μg / mL, 4μg / mL, 2μg / mL, 1μg / mL, 0.5μg / mL, 0.25μg / mL, 0.125μg / mL, and 0.0625μg / mL, and isopsoralea corylifolia chalcone solutions with final concentrations of 8μg / mL, 4μg / mL, 2μg / mL, 1μg / mL, 0.5μg / mL, 0.25μg / mL, 0.125μg / mL, and 0.0625μg / mL. 50 μL of amphotericin B solution was absorbed in the order of concentration from high to low, and added to the A to G rows of the 96-well plate; 50 μL of isopsoralea corylifolia chalcone solution was absorbed in the order of concentration from high to low, and added to the 1st to 8th columns of the 96-well plate. 600 A bacterial suspension of 0.1 was added to each well. Columns 9 and 10 were for the two drugs alone, and column 11 was for the growth control without drugs. In this way, 64 combinations of different concentrations of the two drugs were generated. After the 96-well plate was placed in a 30°C constant temperature incubator and cultured for 24 hours, the results were measured and recorded at 600nm using an ELISA reader. All experiments were repeated 3 times.

[0066] In the experiment, W X , W Y and W XY The OD of fungal cells in the presence of amphotericin B, phytochemicals, and a combination of the two 600nm value relative to the drug-free control group. After incubation, the interaction between amphotericin B and each phytochemical was evaluated using the method reported in the literature ("Functional classification of drugs by properties of their pairwise interactions", Pamela Yeh, Ariane I Tschumi & Roy Kishony, Nature genetics, 38, 489-494, 2006), and an ε~ value was introduced to define the interaction relationship between amphotericin B and the phytochemicals used. ε~ was calculated according to the formula:

[0067]

[0068] Among them, W XY , W X , W Y They represent the quantitative indicators of the effects of drug interactions or single drugs on cell growth in experiments. Specifically: W XY It represents the normalized ratio of the relative decrease in cell growth rate when two drugs X and Y are used in combination relative to the drug-free condition (g XY / g f ). That is, the combined effect of both drugs X and Y together.

[0069] W X Represents the relative effect of single drug X on cell growth rate compared to the absence of drug, the standardized ratio (g X / g f ), i.e., the effect of drug X alone; W Y It represents the relative effect of single drug Y on cell growth rate. Under drug-free conditions, the standardized ratio (g Y / g f ), that is, the effect of drug Y alone.

[0070] In short, W XY , W X and W Y Represent the effects of the two drugs on cell growth rate, while W XY The total effect of their combined use is then defined by comparing these values: additivity, synergy, antagonistic buffering, or antagonistic inhibition. In W XY >W X W Y When equal to W X and W Y The smaller value of , otherwise 0. Greater than WX and W Y The smaller value of ε~ is set to {(W XY -min[W X ,W Y ]) / (1-min[W X ,W Y ])}+1. When the ε~ value falls within the range of -1 to -0.5, the interaction is defined as synergistic; otherwise, it is classified as additive or antagonistic. The specific test results are shown in Table 5.

[0071] Table 5: Combined effects of IBC and AMB

[0072]

[0073] Collaborative definition: If The combination of the two drugs has a synergistic effect.

[0074] From the data in Table 5, it can be seen that the minimum inhibitory concentrations of the combination of isopsoralea chalcone and amphotericin B against Cryptococcus neoformans H99 were 4 μg / mL and 0.125 μg / mL, respectively; The results showed that the combined use of amphotericin B and isopsoralea corylifolia chalcone exerted a synergistic bactericidal effect against Cryptococcus neoformans H99.

[0075] Example 3: Time-killing test

[0076] Cryptococcus neoformans H99 was activated twice in YPD culture medium and cultured at 30°C with shaking at 200 rpm to keep the fungus in the late exponential growth phase. 1 mL of the culture medium was taken, centrifuged and resuspended in physiological saline. The blood cell count was adjusted to a bacterial density of 10 8 CFU / ml. This bacterial solution was diluted to 10 with RPMI-1640 4 CFU / mL, and divided into 2 groups (experimental group and control group), 20mL each. 20mL of RPMI-1640 culture medium was added to the control group. Drugs were added to the experimental group to obtain a single or mixed solution with a final concentration of 4μg / mL psoralea chalcone and 0.125μg / mL amphotericin B, so that the concentration of psoralea chalcone in the experimental group was 4μg / mL, and the concentration of amphotericin B was 1μg / mL and 0.125μg / mL. In addition, the present invention also explores the effect of the combined use of psoralea chalcone and fluconazole against Cryptococcus neoformans, with a drug concentration of 1μg / mL psoralea chalcone and 0.125μg / mL fluconazole. Then cultured at 30°C, and OD was measured after 0, 2, 4, 6, 8, 10, 12, and 24 hours, respectively. 600 For detailed results, see the attached Figure 3 Shown

[0077] By the attached Figure 3 The data show that the growth curves of the control group (isopsoralea chalcone 4 μg / mL, amphotericin B 0.125 μg / mL alone, isopsoralea chalcone 1 μg / mL and fluconazole B 0.125 μg / mL and no drug group) and the experimental group of the present invention (isopsoralea chalcone 4 μg / mL and amphotericin B 0.125 μg / mL) are significantly different, and the experimental group can effectively inhibit the proliferation of bacteria due to the effect of the drugs on the bacteria, showing significant antibacterial activity.

[0078] Example 4: Drug sensitivity test

[0079] In this example, based on Examples 1-3, the above Cryptococcus neoformans H99 bacterial solution was diluted to OD 100 using RPMI-1640 medium. 600 The concentration of the bacterial solution was about 0.2. The cells were divided into 4 groups. Each group took 2 mL of bacterial solution and added it to a glass test tube. One group added isopsoralea chalcone solution to make the concentration of isopsoralea chalcone in the system reach 4 μg / mL. Another group added amphotericin B solution to make the final concentration 0.125 μg / mL. The third group added two different concentrations of drugs in combination, and the last group did not add drugs. After culturing at 30°C for 24 hours. The bacterial solution was diluted by 10 5 times. And from 10 3 , 10 4 , 10 5 5 μL of each dilution was applied to a YPD plate and cultured at 30°C for 48 h. The photos were then taken. For specific results, see the attached Figure 4 shown.

[0080] Attached Figure 4 The growth of the bacteria on YPD plates after treatment with 4μg / mL and 0.125μg / mL of the single drug and the combination of the two drugs was shown in Figure 2. Figure 4 The data show that the combined drug treatment has a significant inhibitory effect on Cryptococcus neoformans, and when the concentration of any drug increases, it shows a significant bactericidal ability. Therefore, after IBC treatment, the sensitivity of Cryptococcus neoformans H99 to amphotericin B is significantly enhanced. In comparison, the combined use of isopsoralea chalcone and fluconazole against Cryptococcus neoformans is not ideal.

[0081] In summary, combined with the characteristics of Chinese herbal medicine extracts as potential antibacterial drugs that are not easy to develop drug resistance, the single product of isopsoralea chalcone can be extracted and purified by natural plants to inhibit the growth of Cryptococcus neoformans H99. And the combined use of isopsoralea chalcone and amphotericin B can effectively reduce the drug concentration and achieve a good fungal inhibition effect. Reducing the drug concentration of amphotericin B can effectively alleviate the current clinically significant fungal resistance to amphotericin B. At the same time, when using low concentrations of IBC for pretreatment, the resistance of Cryptococcus neoformans H99 to amphotericin B can be effectively reduced. Therefore, it can effectively alleviate fungal infections and reduce mortality. As an active substance in traditional Chinese medicine, it can reduce the toxic and side effects of drugs, in order to provide new ideas for the development of new drugs against Cryptococcus neoformans H99 infection.

[0082] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. An antifungal compound pharmaceutical composition, It is characterized in that The compound medicine composition comprises isopsoralea corylifolia chalcone and amphotericin B.

2. The antifungal compound pharmaceutical composition according to claim 1, It is characterized in that The fungus is Cryptococcus neoformans.

3. The antifungal compound pharmaceutical composition according to claim 1, It is characterized in that The mass ratio of the isopsoralea corylifolia chalcone to amphotericin B is 0.0625-8:0.0625-8.

4. The antifungal compound pharmaceutical composition according to claim 1, It is characterized in that The minimum inhibitory concentrations of the combined use of isopsoralea chalcone and amphotericin B on Cryptococcus neoformans are 4-8 μg / mL of isopsoralea chalcone and 0.125-1 μg / mL of amphotericin B, respectively.

5. The antifungal compound pharmaceutical composition according to claim 4, It is characterized in that The minimum inhibitory concentrations of the combined use of isopsoralea chalcone and amphotericin B against Cryptococcus neoformans are 4 μg / mL of isopsoralea chalcone and 0.125 μg / mL of amphotericin B, respectively.

6. The antifungal compound pharmaceutical composition according to any one of claims 1 to 5, It is characterized in that The compound pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

7. The antifungal compound pharmaceutical composition according to claim 6, It is characterized in that The pharmaceutically acceptable excipients are selected from at least one of pharmaceutically acceptable solvents, solubilizers, cosolvents, adhesives, emulsifiers, colorants, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, preservatives, flavoring agents, suspending agents, coating materials, fragrances, anti-adhesives, pH regulators, integrators, penetration enhancers, buffers, plasticizers, surfactants, humectants, thickeners, inclusion agents, absorbents, release retardants, diluents, flocculants and deflocculating agents, filter aids, polymer skeleton materials and film-forming materials.

8. The antifungal compound pharmaceutical composition according to claim 6, It is characterized in that The compound pharmaceutical composition is a capsule, gel, cream, mixture, tablet, powder, pill, granule, wet compress, solution, syrup, suppository, decoction, aerosol, ointment, plaster, injection, spray, tincture, liniment, paste or lotion.

9. Use of the antifungal compound pharmaceutical composition according to any one of claims 1 to 5 in the preparation of an anti-Cryptococcus neoformans drug.

10. Use of the antifungal compound pharmaceutical composition according to claim 9 in the preparation of an anti-cryptococcus neoformans drug, It is characterized in that The anti-Cryptococcus neoformans includes inhibiting the growth of Cryptococcus neoformans, killing Cryptococcus neoformans and / or treating diseases caused by Cryptococcus neoformans infection; and / or, the isopsoralea chalcone can reduce the dosage of amphotericin B used on Cryptococcus neoformans and the anti-Cryptococcus neoformans effect.

Citation Information

Patent Citations

  • Application of isobavachalcone in preparation of medicine for inhibiting cryptococcus neoformans infection

    CN116421588A

  • Application of isobavachalcone and fluconazole combined drug in preparation of antifungal drugs

    CN117679412A